Visual EHDS 19.02

The BioMed Alliance has published a new statement in light of the trilogue discussions on the proposal for a European Health Data Space. Medical societies, and the healthcare professionals and researchers that they represent, welcome the intention of the proposal to facilitate health data sharing for healthcare and research, if the necessary elements are in place. However, some of the provisions that are currently being discussed could lead to fragmentation, legal uncertainty and data bias in the datasets that will be available for research within EHDS.

Read our recommendations here.

New vacancy 02.24

Start: March 2024

The Biomedical Alliance in Europe is a not-for-profit organisation representing 34 leading European associations devoted to medical care and biomedical research. It represents more than 400,000 researchers and health professionals (www.biomedeurope.org).

The BioMed Alliance’s principal goals and objectives are to promote the aims and values of researchers, healthcare professionals and not-for-profit European medical associations and organisations across all medical disciplines.

We facilitate cooperation between our members and represent them in policy and advocacy issues related to health research, continuing medical education and regulatory affairs, including Medical Devices, Academic Clinical Trials, In Vitro Diagnostics and health data sharing. Succinctly, we act as a single voice on transversal health and health research issues, to facilitate multi-stakeholder communication at European level.

Location:

Rue de la Loi 34/36, Brussels

Description:

You will be part of a small team that is responsible for supporting collaboration and communication among the member organisations. You will be involved in the organization of events, communication, the development of advocacy actions, engagement and capacity building with EU decision makers and EU health stakeholders and in providing information to member organizations.

 Responsibilities:

  • monitor the EU policy agenda (research and health related)
  • support the team in developing policy campaigns and help implement a broad range of advocacy activities
  • draft reports, minutes and policy briefings
  • actively develop and maintain a network of contacts and use contact management tools such as contact databases
  • support the team in drafting newsletters and communication activities related to the organization’s activities
  • organise meetings and events
  • communicate with a broad network of professionals, experts and policy makers

 Candidate Profile

  • You are highly proficient in spoken and written English, as our work is exclusively carried out in that language.
  • You have good writing and analytical skills.
  • You have a genuine enthusiasm for public affairs & advocacy and an appetite to discover the not-for-profit universe.
  • You have an interest in health and research policy or would like to learn more about these policy areas.
  • You should have an outstanding academic record to be able to deal with the multidisciplinary aspects of the role.
  • You are an EU citizen or holder of a Belgian work permit

 What we offer:

We provide a friendly working environment and the opportunity to acquire excellent professional experience with the purpose to help in starting your career. You will also be able to enhance your knowledge of EU affairs, health and research policy and the activities of medical & research societies.

Description of the proposed contract:

You will start with 6 months of internship followed by a full employment contract of 6 months. The contract is remunerated and could be prolonged after the 1-year commitment. The position is under the “Formation Professionelle en Entreprise (FPI)’s rules proposed by Bruxelles Formation. To be eligible for this type of contract, you must be enrolled in the Actiris platform.

Interested?

Please send your CV, and a short news item written by you on a topic that you consider of interest for the Biomed Alliance, to our Executive Director Loredana Simulescu: This email address is being protected from spambots. You need JavaScript enabled to view it. no later than 19 February.

Read our new January Update, to get an update on BioMed Alliance activities and new developments in the EU policy sphere. In this edition you will find more information about our newest member, a statement and Commission proposal on extended transition periods for IVDs, our participation in an event on genomic data in EHDS, a consultation on the Cross-Border Threats to Health Regulation, IHI Call 6 & 7 that are open now, our presentation at the HERA board on our recent discussion paper, members news and upcoming events.

The BioMed Alliance is proud to welcome a new member, the European Society for Clinical Cell Analysis (ESCCA). We look forward to working with this newest member to continue to raise awareness on the perspectives of medical and research societies across Europe.

ESCCA is a scientific society founded to ensure the continuation of the activities of the European Working Group on Clinical Cell Analysis (EWGCCA). EWGCCA was formed in 1996 with a Biomed-2 grant in order to establish collaboration between sixteen European centres that use and develop flow cytometric applications mainly for clinical purposes. Since 1996 EWGCCA has organised very successful annual European Courses and Euroconferences aimed at the standardisation, validation and dissemination of flow cytometric know-how and its implementation in clinical laboratories. The Courses and Conferences have included presentations by high-profile speakers from the USA. The annual ESCCA European Courses now rank among the world’s largest educational events in flow cytometry.

BioMed Alliance Statement

In a new statement, BioMed Alliance highlights its increasing concerns about approaching widespread issues with the availability of In Vitro Diagnostic Devices (IVDs) in Europe. Persisting problems with the implementation of the In Vitro Diagnostics Regulation (IVDR), insufficient certificates issued, the failure to deliver the EUDAMED database and general unpreparedness of the sector could lead to the disappearance from the market of a large number of essential IVDs in the near future and related loss of international competitivity compared to other jurisdictions. The document calls for a mix of short-term solutions (including an extension of the transition period) and more longer-term reforms of the system to ensure pressing challenges are addressed.

Read more here